Targeting cell division cycle 7 kinase: A new approach for cancer therapy

101Citations
Citations of this article
95Readers
Mendeley users who have this article in their library.

Abstract

The cell division cycle 7 (Cdc7) is a serine-threonine kinase, originally discovered in budding yeast, required to initiate DNA replication. Human Cdc7 phosphorylates the minichromosome maintenance protein 2 (Mcm2), a component of the DNA replicative helicase needed for genome duplication. Inhibition of Cdc7 in cancer cells impairs progression through S phase, inducing a p53-independent apoptotic cell death, whereas in normal cells, it does not affect cell viability. Small molecule compounds able to interfere with Cdc7 activity have been identified and shown to be effective in controlling tumor growth in animal models. Two Cdc7 inhibitors are currently in phase I clinical development. Inhibition of Cdc7 kinase activity in cancer cells restricts DNA replication and induces apoptotic cell death by an unprecedented molecular mechanism of action. ©2010 AACR.

Cite

CITATION STYLE

APA

Montagnoli, A., Moll, J., & Colotta, F. (2010, September 15). Targeting cell division cycle 7 kinase: A new approach for cancer therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-10-0185

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free